Julius Knowles

CIK: 0001808365

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KROS

Keros Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

KROS
Keros Therapeutics, Inc.
Jun 4, 2026
Sale(S)
Direct
2.6K shares at avg. $10.73$28K
KROS
Keros Therapeutics, Inc.
Jun 3, 2026
Award(A)
Direct
7.1K shares-
KROS
Keros Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Indirect
191.5K shares at avg. $17.75$3.4M
KROS
Keros Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Indirect
130.5K shares at avg. $17.75$2.3M
KROS
Keros Therapeutics, Inc.
Jun 4, 2025
Award(A)
Direct
5.3K shares-

		Type	Shares	Price		Ownership
Jun 4, 2026	KROS Keros Therapeutics, Inc.	Sale(S)	2,625	$10.73	$28,166	Direct
Jun 3, 2026	KROS Keros Therapeutics, Inc.	Award(A)	7,142	-	$0	Direct
Nov 21, 2025	KROS Keros Therapeutics, Inc.	Disposition(D)	191,527	$17.75	$3,399,604	Indirect
Nov 21, 2025	KROS Keros Therapeutics, Inc.	Disposition(D)	130,494	$17.75	$2,316,269	Indirect
Jun 4, 2025	KROS Keros Therapeutics, Inc.	Award(A)	5,250	-	-	Direct

1-5 of 5 transactions

About Knowles Julius

Knowles Julius (SEC CIK 0001808365) files insider reports with the SEC as Director of Keros Therapeutics, Inc. (KROS).

Signal8 holds 4 ownership filings by Knowles Julius, all Form 4s, filed between Jun 6, 2025 and Jun 8, 2026. Those filings report 5 transactions, from Jun 4, 2025 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Knowles Julius's filings is in LEXINGTON, MA.

Recent filings by Knowles Julius

Jun 4, 2026: Open-market sale of KROS shares (Form 4, code S).
Jun 3, 2026: Grant or award of KROS shares (Form 4, code A).
Nov 21, 2025: Disposition to issuer transactions of KROS shares (2 lines, Form 4, code D).
Jun 4, 2025: Grant or award of KROS shares (Form 4, code A).

Other insiders filing for Keros Therapeutics, Inc. (KROS)

Tanini Annita, Corp. Controller & VP, Finance
Lerner Lorena Raquel, Chief Scientific Officer
Cho Esther, Chief Legal Officer
Newton Charles W., Director
BIENAIME JEAN JACQUES, Director
Prener Anne, Director

How to read Form 4 transaction codes